From: Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
Score
Risk
Disposition
0, or 1
1.5% mortality
Outpatient care
2
9.2% mortality
Inpatient vs observation admission
≥ 3
22% mortality
Inpatient admission with consideration for ICU admission with score of 4 or 5